Medication monitoring in a nurse-led respiratory outpatient clinic: pragmatic randomised trial of the West Wales Adverse Drug Reaction Profile

Marie E Gabe, Fiona Murphy, Gwyneth A Davies, Ian T Russell, Susan Jordan, Marie E Gabe, Fiona Murphy, Gwyneth A Davies, Ian T Russell, Susan Jordan

Abstract

Objective: To assess the clinical effect of medication monitoring using the West Wales Adverse Drug Reaction (ADR) Profile for Respiratory Medicine.

Design: Single-site parallel-arm pragmatic trial using stratified randomisation.

Setting: Nurse-led respiratory outpatient clinic in general hospital in South Wales.

Participants: 54 patients with chronic respiratory disease receiving bronchodilators, corticosteroids or leukotriene receptor antagonists.

Intervention: Following initial observation of usual nursing care, we allocated participants at random to receive at follow up: either the West Wales ADR Profile for Respiratory Medicine in addition to usual care ('intervention arm' with 26 participants); or usual care alone ('control arm' with 28 participants).

Main outcome measures: Problems reported and actions taken.

Results: We followed up all randomised participants, and analysed data in accordance with treatment allocated. The increase in numbers of problems per participant identified at follow up was significantly higher in the intervention arm, where the median increase was 20.5 [inter-quartile range (IQR) 13-26], while that in the control arm was -1 [-3 to +2] [Mann-Whitney U test: z = 6.28, p<0.001]. The increase in numbers of actions per participant taken at follow up was also significantly higher in the intervention arm, where the median increase was 2.5 [1]-[4] while that in the control arm was 0 [-1.75 to +1] [Mann-Whitney U test: z = 4.40, p<0.001].

Conclusion: When added to usual nursing care, the West Wales ADR Profile identified more problems and prompted more nursing actions. Our ADR Profile warrants further investigation as a strategy to optimise medication management.

Trial registration: Controlled-trials.com ISRCTN10386209.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow of participants through the…
Figure 1. Flow of participants through the trial.
Figure 2. Bar chart of problems found…
Figure 2. Bar chart of problems found and actions taken par participant at observations one and two.

References

    1. Baines RJ, Langelaan M, de Bruijne MC, Asscheman H, Spreeuwenberg P, et al. (2013) Changes in adverse event rates in hospitals over time: a longitudinal retrospective record review. Quality and Safety in Health Care 22: 290–298.
    1. Aronson JK (2013) Adverse drug reactions: history, terminology, classification, causality, frequency, preventability In: Talbot J, Aronson JK, editors. Stephens’ Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edtn. Chichester, UK: Wiley-Blackwell 1–119.
    1. International Conference of Harmonization (1996) ICH Harmonised Tripartite Guideline for Good Clinical Practice. Buckinghamshire, UK: Institute of Clinical Research. Available: (accessed 09 September 2010)
    1. Howard R, Avery A, Slavenburg S, Royal S, Pipe G, et al. (2007) Which drugs cause preventable admissions to hospital? A systematic review. British Journal of Clinical Pharmacology 63: 136–147.
    1. Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, et al. (2010) Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. Journal of the Royal Society of Medicine 103: 239–250.
    1. Ferner RE, Butt TF (2012) Adverse drug reactions. Medicine 40: 366–370.
    1. Cunningham G, Dodd TRP, Grant DJ, McMurdo MET, Richards RME, et al (1997) Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age and Ageing 26: 375–382.
    1. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, et al. (2000) Incidence and preventability of adverse drug events in nursing homes. American Journal of Medicine 109: 87–94.
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 329: 15–19.
    1. Hakkarainen KM, Hedna K, Petzold M, Hägg S (2013) Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis. PLoS ONE 7: e33236.
    1. Kvasz M, Allen IE, Gordon MJ, Ro EY, Estok R, et al. (2000) Adverse Drug Reactions in Hospitalised Patients: A Critique of a Meta-analysis. Medscape General Medicine 2: E3.
    1. Beijer HJM, de Blaey CJ (2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science 24: 46–54.
    1. Miguel A, Azevedo LF, Araújo M, Pereira AC (2012) Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety 21: 1139–1154.
    1. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. Journal of the American Medical Association 279: 1200–1205.
    1. Yee JL, Hasson NK, Schreiber DH (2005) Drug-related emergency department visits in an elderly veteran population. Annals of Pharmacotherapy 39: 1990–1995.
    1. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Saljé K, et al. (2011) Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiology and Drug Safety 20: 626–634.
    1. Hohl CM, Nosyk B, Kuramoto L, Zed PJ, Brubacher JR, et al. (2011) Outcomes of emergency department patients presenting with adverse drug events. Annals of Emergency Medicine 58: 270–279.
    1. National Patient Safety Agency (2007) Safety in doses: medication safety incidents in the NHS. London, UK: National Patient Safety Agency. Available: Accessed 12 April 2014
    1. Glasziou P, Aronson J (2008) An introduction to monitoring therapeutic interventions in clinical practice. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence based medical monitoring. Oxford, UK: Blackwell publishing/BMJ books. 3–14.
    1. Jordan S (2011) Adverse events: expecting too much of nurses and too little of nursing research. Journal of Nursing Management 19: 287–292.
    1. Health Service Commissioner for England (2011) Care and Compassion? Report of the Health Service Ombudsman on ten investigations into NHS care of older people. [Online]. London, UK: Parliamentary and Health Service Ombudsman, The Stationery Office. Available: Accessed 8 May 2013.
    1. Gabe ME (2012) Nurse-led medication monitoring and adverse events. PhD Thesis, Swansea University, UK.
    1. Jha AK, Prasopa-Plaizier N, Larizgoitia I (2010) Bates DW; Research Priority Setting Working Group of the WHO World Alliance for Patient Safety (2010) Patient safety research: an overview of the global evidence. Quality and Safety in Health Care 19: 42–47.
    1. Jordan S (2007) Adverse Drug Reactions: Reducing the Burden of Treatment. Nursing Standard 21(34): 35–41.
    1. Brenner S, Detz A, López A, Horton C, Sarkar U (2012) Signal and noise: applying a laboratory trigger tool to identify adverse drug events among primary care patients. BMJ Quality and Safety 21: 670–675.
    1. Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, et al. (1998) Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. European Journal of Clinical Pharmacology 54: 483–488.
    1. Blenkinsopp A, Wilkie P, Wang M, Routledge PA (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. British Journal of Clinical Pharmacology 63: 148–156.
    1. Urinary Tract Infection Study Group (1987) Coordinated multicenter study of norfloxacin versus trimethroprim-sulfarnethoxazole treatment of symptomatic urinary tract infections. Journal of Infectious Disease 155: 170–177.
    1. Medawar C, Herxheimer A (2003) A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior with paroxetine. International Journal of Risk and Safety in Medicine 16: 5–19.
    1. Gandhi T, Weingart S, Borus J, Seger AC, Peterson J, et al. (2003) Adverse drug events in ambulatory care. New England Journal of Medicine 348: 1556–1564.
    1. Lorimer S, Cox A, Langford NJ (2012) A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. Journal of Clinical Pharmacy and Therapeutics 37: 148–152.
    1. van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K (2012) Experiences with Adverse Drug Reaction Reporting by Patients. An 11-Country Survey. Drug Safety 35: 45–60.
    1. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, et al. (2011) Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technology Assessment 15(20): 1–234, iii–iv. doi:10.3310/hta15200.
    1. Fortnum H, Lee AJ, Rupnik B, Avery AJ, Yellow Card Study Collaboration (2012) Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. Journal of Clinical Pharmacy and Therapeutics 37: 161–165.
    1. Aziz Z, Siang TC, Badarudin NS (2007) Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiology and drug safety 16: 223–228.
    1. Gonzàlez-Rubio F, Calderón-Larrañaga1 F, Poblador-Plou B, Navarro-Pemán C, López-Cabañas A, et al (2011) Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiology and Drug Safety 20: 1287–1294.
    1. Molokhia M, Tanna S, Bell D (2009) Improving reporting of adverse drug reactions: Systematic review. Clinical Epidemiology 1: 75–92.
    1. Gurwitz JH, Field TS, Judge J Rochon P, Harrold LR, et al. (2005) The incidence of adverse drug events in two large academic long-term care facilities. The American Journal of Medicine 118: 251–258.
    1. National Co-ordinating Council for Medication Error Reporting and Prevention (2005) The First Ten Years “Defining the Problem and Developing Solutions”. United States Pharmacopia, Rockville, Maryland. Available: Accessed 8 May 2013.
    1. Steinman MA, Handler SM, Gurwitz JH, Schiff GD, Covinsky KE, et al. (2011) Beyond the prescription: Medication monitoring and adverse drug events in older adults. Journal of the American Geriatrics Society 59: 1513–1520.
    1. McKibbon KA, Lokker C, Handler SM, Dolovich LR, Holbrook AM, et al. (2012) The effectiveness of integrated health information technologies across the phases of medication management: a systematic review of randomized controlled trials. Journal of the American Medical Informatics Association 19: 22–30.
    1. Shojania KG, Thomas EJ (2013) Trends in adverse events over time: why are we not improving? Quality and Safety in Health Care 22: 273–277.
    1. O’Leary KJ, Devisetty VK, Patel AR, Malkenson D, Sama P, et al. (2013) Comparison of traditional trigger tool to data warehouse based screening for identifying hospital adverse events. Quality and Safety in Health Care 22: 130–138.
    1. American Lung Association (2011) Fighting for Air. Available: Accessed 8 May 2013.
    1. European Lung Foundation (2011) Lung Health in Europe. Facts and Figures. Available: Accessed 8 May 2013.
    1. The British Thoracic Society (2006) The Burden of Lung Disease. A Statistics Reports from the British Thoracic Society. 2nd Edtn. Available: Accessed 8 May 2013.
    1. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, et al. (2009) Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes. PloS ONE. 4: e4439.
    1. British Thoracic Society/Scottish Intercollegiate Guidelines Network (2011) Asthma Guideline. Available: Accessed 8 May 2013.
    1. Global Initiative for Chronic Obstructive Lung Disease (2011) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011.Available: Accessed 8 May 2013.
    1. Aronson JK (2006) Meyler’s Side Effects of Drugs: The International Encyclopaedia of Adverse Drug Reactions and Interactions. Amsterdam, Elsevier.
    1. Lewis KE, Davies GA (2010) Drugs that act on the respiratory tract. In: Aronson JK editor Side Effects of Drugs Annual 32. Amsterdam: Elsevier. 311–331.
    1. Jordan S (2008) The Prescription Drug Guide for Nurses. Maidenhead, UK: Open University Press, McGraw-Hill.
    1. British National Formulary (2013) BNF number 65. London, UK: British Medical Association and the Royal Pharmaceutical Society of Great Britain.
    1. Gabe ME, Jordan S (2013) Development and clinical gains of nurse-led medication monitoring profiles. Journal of Nursing Management: doi:10.1111/jonm.12067. [Epub ahead of print].
    1. Deshmukh CT (2007) Minimizing side effects of systemic corticosteroids in children. Indian Journal of Dermatology, Venereology and Leprology 73(4): 218–221.
    1. Lewis DA, Smith RE (1983) Steroid-induced Psychiatric Syndromes. A Report of 14 Cases and a Review of the Literature. Journal of Affective Disorders 5(4): 319–332.
    1. Schimmer B, Parker K (2006) Adrenocortiotropic hormone; adrenocortical steroids and their synthetic analogues. In: Brunton, L., Lazo J., Parker K. (editors) Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 11th edition. New York; McGraw-Hill. 1587–1612.
    1. Sirois F (2003) Steroid psychosis: a review. General Hospital Psychiatry 25(1): 27–33.
    1. Russell D, Hoare ZS, Whitaker R, Whitaker CJ, Russell IT (2011) Generalized method for adaptive randomization in clinical trials. Statistics in Medicine 30: 922–934.
    1. Jordan S (2002) Managing Adverse Drug Reactions: An Orphan Task. Developing Nurse-Administered Evaluation Checklists. Journal of Advanced Nursing 38: 437–448.
    1. Jordan S, Tunnicliffe C, Sykes A (2002) Minimising Side Effects: The clinical impact of nurse-administered ‘side effect’ checklists. Journal of Advanced Nursing 37: 155–165.
    1. Uitenbroek DG (1997). SISA (Simple Interactive Statistical Analysis) Binomial. Southampton. Available: . Accessed 8 May 2013.
    1. Dilles T, Elseviers MM, Van Rompaey B, Van Bortel LM, Stichele RR (2011) Barriers for nurses to safe medication management in nursing homes. Journal of Nursing Scholarship 43: 171–180.
    1. Lapane KL, Hughes CM, Daiello LA, Cameron KA, Feinberg J (2011) Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes. Journal of the American Geriatrics Society 59: 1238–1245.
    1. Nash M (2011) Improving mental health service users’ physical health through medication monitoring: A literature review. Journal of Nursing Management 19: 360–365.
    1. Jarernsiripornkul N, Senacom P, Uchaipichat V, Chaipichit N, Krska J (2012) Patient reporting of suspected adverse drug reactions to antiepileptic drugs: Factors affecting attribution accuracy. Epilepsy and Behaviour 24: 102–106.
    1. Welsh Assembly Government (2005) Designed for Life: creating world class Health and Social Care for Wales in the 21st Century. Cardiff, UK: Welsh Assembly Government.
    1. Altman DG (1985) Comparability of randomised groups. The Statistician 34: 125–136.
    1. Altman DG, Bland JM (1999) Statistics notes. Treatment allocation in controlled trials: why randomise? British Medical Journal 318: 1209.
    1. Morello RT, Lowthian JA, Barker A McGinnes R, Dunt D, et al. (2013) Strategies for improving patient safety culture in hospitals: a systematic review. Quality and Safety in Health Care 22: 11–18.
    1. Caplan L, Haverhals LM (2012) Barriers and facilitators for preventing adverse drug reactions of long latency: a qualitative study. International Journal of Risk and Safety in Medicine 24: 81–94.
    1. Bell JS, Enlund H, Vainio K (2010) Medication adherence: a review of pharmacy education, research, practice and policy in Finland. Pharmacy Practice 8: 147–161.
    1. Närhi U, Airaksinen M, Enlund H (2002) Pharmacists solving problems in asthma management – experiences from a one-year intervention programme in Finland. International Journal of Pharmacy Practice 10: 55–59.
    1. Närhi U, Airaksinen M, Tanskanen P, Erlund H (2000) Therapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. Journal of Clinical Pharmacy and Therapeutics 25: 177–183.
    1. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, et al. (2001) Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age and Ageing 30: 205–211.
    1. Bultman DC, Svarstad BL (2002) Effects of Pharmacists Monitoring on Patient Satisfaction with Antidepressant Medication Therapy. Journal of the American Pharmacist Association 42: 36–43.
    1. Jordan S, Coleman M, Hardy B, Hughes D (1999) Assessing Educational Effectiveness: The Impact Of A Specialist Course On The Delivery Of Care Journal of Advanced Nursing. 30: 796–807.
    1. Kyriacos U, Jordan S, Van Den Heever J (2005) The biological sciences in nursing: a developing country perspective. Journal of Advanced Nursing 52: 91–103.
    1. Cleary A, Walsh F, Connolly H, Hays V, Oluwole B, et al. (2011) Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. Journal of Psychiatric and Mental Health Nursing 19: 395–401.
    1. Chopra V, Shojania KG (2013) Recipes for checklists and bundles: one part active ingredient, two parts measurement. Quality and Safety in Health Care 22: 93–96.
    1. Winkeljohn D (2010) Adherence to oral cancer therapies: Nursing interventions. Clinical Journal of Oncology Nursing 14: 461–466.
    1. Gabe ME, Davies GA, Murphy F, Davies M, Johnstone L, et al. (2011) Adverse drug reactions: treatment burdens and nurse-led medication monitoring. Journal of Nursing Management 19: 377–392.
    1. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358: 1872–1873.
    1. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Safety 29: 385–396.
    1. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. British Medical Journal 343: d5928 10.1136/bmj.d5928
    1. Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, et al. (2007) Contamination in trials of education interventions. Health technology Assessment 11(43): iii, ix-107.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, et al. (2008) Extending the CONSORT Statement to Randomized Trials of Nonpharmacological Treatment: Explanation and Elaboration. Annals of Internal Medicine 148: 295–309.
    1. Eldridge S (2010) Pragmatic trials in primary health care: what, when and how? Family Practice 27(6): 591–592.
    1. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, et al. (2008) Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 337: a2390 1223–1226.
    1. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Oxford, UK: The Cochrane Collaboration. Available: : 13 December 2013.
    1. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, et al. (2012) Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 344: e1119 10.1136/bmj.e1119
    1. Rosenthal R, Jacobson L (1963) Teachers’ expectancies: Determinants of pupils’ IQ gains. Psychological Reports 19: 115–118.
    1. Schulz K, Grimes DA (2006) The Lancet handbook of essential concepts in clinical research. Edinburgh: Elsevier.
    1. Shadish SW, Cook TD, Campbell DT (2002) Experimental and quasi-experimental designs for generalized causal inferences. New York: Houghton Mifflin.
    1. Post PN, de Beer H, Guyatt GH (2012) How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches. Journal of Evaluation in Clinical Practice doi:–10.1111/j.13652753.2012.01888.x
    1. Jordan S, Watkins A, Storey M, Allen SJ, Brooks CJ, et al. (2013) Volunteer Bias in Recruitment, Retention, and Blood Sample Donation in a Randomised Controlled Trial Involving Mothers and Their Children at Six Months and Two Years: A Longitudinal Analysis. PLoS ONE 8(7): e67912 10.1371/journal.pone.0067912
    1. Golder S, Loke Y (2009) Search strategies to identify information on adverse effects: a systematic review. Journal of the Medical Library Association 97(2): 84–92.
    1. Tsang R, Colley L, Lynd LD (2009) Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. Journal of Clinical Epidemiology 62: 609–16.
    1. Audit Commission (2001) A Spoonful of Sugar: Medicines Management in NHS Hospitals. London, UK: The Stationery Office.
    1. Committee of Public Accounts (2006) A Safer Place for Patients: Learning to Improve Patient Safety. London, UK: The Stationery Office.
    1. Francis R (2013) Report of the Mid Staffordshire NHS Foundation Trust Public Inquiry: Executive Summary. London, UK: The Stationery Office. Available: . Accessed 15 December 2013.
    1. Jarernsiripornkul N, Krska J, Capps PAG, Richards RM, Lee A (2002) Patient reporting of potential adverse drug reactions: a methodological study. British Journal of Clinical Pharmacology 53: 318–325.
    1. Montesi G, Lechi A (2009) Prevention of medication errors: detection and audit. British Journal of Clinical Pharmacology 67: 651–655.
    1. de Vries EN, Prins HA, Crolla RM, den Outer AJ, van Andel G, et al. (2010) Effect of a comprehensive surgical safety system on patient outcomes. New England Journal of Medicine 363: 1928–1937.
    1. Arditi C, Rège-Walther M, Wyatt JC, Durieux P, Burnand B (2012) Computer-generated reminders delivered on paper to healthcare professionals; effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 12: CD001175 10.1002/14651858.CD001175.pub3
    1. Onder G, van der Cammen TJ, Petrovic M, Somers A, Rajkumar C (2013) Strategies to reduce the risk of iatrogenic illness in complex older adults. Age Ageing 42: 284–91 10.1093/ageing/aft038
    1. Loke YK (2013) An agenda for UK clinical pharmacology: Adverse drug reactions. British Journal of Clinical Pharmacology 73: 908–911.
    1. Herxheimer A, Sanz E (2008) Social, cultural and ethical aspects of drug use–changes over 40 years: a personal look back. European Journal of Clinical Pharmacology 64: 107–114.
    1. Jordan S (2009) Medication Errors In An Intensive Care Unit: Systems, Pressures And Prioritising. Journal Of Advanced Nursing 16: 2258–2259.
    1. Thompson A, Hetrick SE, Alvarez-Jiménez M, Parker AG, Willet M, et al. (2011) Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. The Australian and New Zealand Journal of Psychiatry 45: 740–748.
    1. Wightman R, Fielding J, Green S (2011) Audit of antipsychotic prescribing in dementia: Cambridgeshire results and lessons learnt. Psychiatria Danubina 23: S126–129.
    1. Hill KD, Wee R (2012) Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs and Aging 29: 15–30.
    1. Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, et al. (2014) Medication Monitoring for People with Dementia in Care Homes: the Feasibility and Clinical Impact of Nurse-led monitoring. The Scientific World Journal Article ID 843621. doi:10.1155/2014/843621. Available: 12 April 2014
    1. Department of Health (2008) Medicines Management: Everybody’s Business. London, UK: The Stationery Office.
    1. Department of Health (2000) A health Service of all the talents: Developing the NHS workforce. London, UK: The Stationery Office.
    1. Tierney W (2003) Adverse outpatient drug events – a problem and opportunity. New England Journal of Medicine 348: 1587–1589.
    1. Lampela P, Hartikainen S, Sulkava R, Huupponen R (2007) Adverse drug effects in elderly people – a disparity between clinical examination and adverse effects self-reported by the patient. European Journal of Clinical Pharmacology 63: 509–515.
    1. Valentin A, Capuzzo M, Guidet B, Moreno R, Metnitz B, et al. (2009) Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ 12: b814 10.1136/bmj.b814
    1. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates D (2005) Adverse drug events occurring following hospital discharge. Journal of General Internal Medicine 20: 317–323.
    1. Mant D (2008) A framework for developing and evaluating a monitoring strategy. In: Glasziou P, Irwig L, Aronson JK, editors Evidence based medical monitoring. Oxford, UK: Blackwell publishing/BMJ books. 15–30.
    1. Coleman J, Ferner R, Aronson J (2008) Monitoring for the adverse effects of drugs. In: Glasziou P, Irwig L, Aronson JK, eds. Evidence based medical monitoring. Oxford, UK: Blackwell publishing/BMJ books. 194–210.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다